UA80673C2 - Stabilized brivudine topical formulation - Google Patents
Stabilized brivudine topical formulation Download PDFInfo
- Publication number
- UA80673C2 UA80673C2 UA2003076388A UA2003076388A UA80673C2 UA 80673 C2 UA80673 C2 UA 80673C2 UA 2003076388 A UA2003076388 A UA 2003076388A UA 2003076388 A UA2003076388 A UA 2003076388A UA 80673 C2 UA80673 C2 UA 80673C2
- Authority
- UA
- Ukraine
- Prior art keywords
- oxide
- titanium dioxide
- water
- brivudine
- pharmaceutical composition
- Prior art date
Links
- 229960001169 brivudine Drugs 0.000 title claims abstract description 51
- ODZBBRURCPAEIQ-PIXDULNESA-N helpin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(\C=C\Br)=C1 ODZBBRURCPAEIQ-PIXDULNESA-N 0.000 title claims abstract description 51
- 239000012049 topical pharmaceutical composition Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 claims abstract description 20
- 239000000049 pigment Substances 0.000 claims abstract description 17
- 229910044991 metal oxide Inorganic materials 0.000 claims abstract description 9
- 150000004706 metal oxides Chemical class 0.000 claims abstract description 9
- 241001529453 unidentified herpesvirus Species 0.000 claims abstract description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 6
- 208000015181 infectious disease Diseases 0.000 claims abstract description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 44
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 38
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 33
- 239000006071 cream Substances 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- 239000004408 titanium dioxide Substances 0.000 claims description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 19
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 17
- 239000003921 oil Substances 0.000 claims description 17
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 16
- -1 polyoxyethylene monostearate Polymers 0.000 claims description 14
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 9
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 claims description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 8
- 235000011187 glycerol Nutrition 0.000 claims description 8
- 229910052814 silicon oxide Inorganic materials 0.000 claims description 8
- 239000003871 white petrolatum Substances 0.000 claims description 8
- 239000011787 zinc oxide Substances 0.000 claims description 8
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 claims description 7
- 241000700605 Viruses Species 0.000 claims description 6
- NJESAXZANHETJV-UHFFFAOYSA-N 4-methylsalicylic acid Chemical compound CC1=CC=C(C(O)=O)C(O)=C1 NJESAXZANHETJV-UHFFFAOYSA-N 0.000 claims description 5
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 5
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 5
- 229940082500 cetostearyl alcohol Drugs 0.000 claims description 5
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 5
- 239000000839 emulsion Substances 0.000 claims description 5
- 239000000017 hydrogel Substances 0.000 claims description 5
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 5
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 5
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 claims description 5
- 239000005662 Paraffin oil Substances 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 235000019271 petrolatum Nutrition 0.000 claims description 4
- 229940075579 propyl gallate Drugs 0.000 claims description 4
- 239000000473 propyl gallate Substances 0.000 claims description 4
- 235000010388 propyl gallate Nutrition 0.000 claims description 4
- 229940051164 ferric oxide yellow Drugs 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 claims description 2
- 229940083037 simethicone Drugs 0.000 claims description 2
- 229940057995 liquid paraffin Drugs 0.000 claims 7
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims 4
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims 4
- 229940045860 white wax Drugs 0.000 claims 4
- WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 claims 3
- SZVJSHCCFOBDDC-UHFFFAOYSA-N ferrosoferric oxide Chemical compound O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 claims 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims 2
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 claims 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims 2
- 239000004166 Lanolin Substances 0.000 claims 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims 2
- 229960000541 cetyl alcohol Drugs 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims 2
- 229940039717 lanolin Drugs 0.000 claims 2
- 235000019388 lanolin Nutrition 0.000 claims 2
- 235000019359 magnesium stearate Nutrition 0.000 claims 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 2
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 claims 2
- ODZBBRURCPAEIQ-DJLDLDEBSA-N Brivudine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C=CBr)=C1 ODZBBRURCPAEIQ-DJLDLDEBSA-N 0.000 claims 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 claims 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- 239000001361 adipic acid Substances 0.000 claims 1
- 235000011037 adipic acid Nutrition 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 claims 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
- 229960002446 octanoic acid Drugs 0.000 claims 1
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 claims 1
- 239000012188 paraffin wax Substances 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
- 238000012876 topography Methods 0.000 claims 1
- 230000000699 topical effect Effects 0.000 abstract description 8
- 239000003381 stabilizer Substances 0.000 abstract description 7
- 238000001782 photodegradation Methods 0.000 abstract description 3
- 208000007514 Herpes zoster Diseases 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 229960004150 aciclovir Drugs 0.000 description 11
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 11
- JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 description 6
- 239000003443 antiviral agent Substances 0.000 description 6
- 229960001179 penciclovir Drugs 0.000 description 6
- JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 5
- 229960005191 ferric oxide Drugs 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 206010067152 Oral herpes Diseases 0.000 description 4
- 208000029433 Herpesviridae infectious disease Diseases 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 230000000176 photostabilization Effects 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- JGUMTYWKIBJSTN-UHFFFAOYSA-N 2-ethylhexyl 4-[[4,6-bis[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 JGUMTYWKIBJSTN-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 208000004898 Herpes Labialis Diseases 0.000 description 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 239000004904 UV filter Substances 0.000 description 2
- 108020005202 Viral DNA Proteins 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 229960004396 famciclovir Drugs 0.000 description 2
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 2
- 238000006303 photolysis reaction Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- MXHRCPNRJAMMIM-SHYZEUOFSA-N 2'-deoxyuridine Chemical class C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-SHYZEUOFSA-N 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229960001716 benzalkonium Drugs 0.000 description 1
- CYDRXTMLKJDRQH-UHFFFAOYSA-N benzododecinium Chemical compound CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 CYDRXTMLKJDRQH-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- TXKMVPPZCYKFAC-UHFFFAOYSA-N disulfur monoxide Inorganic materials O=S=S TXKMVPPZCYKFAC-UHFFFAOYSA-N 0.000 description 1
- XACKNLSZYYIACO-DJLDLDEBSA-N edoxudine Chemical compound O=C1NC(=O)C(CC)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XACKNLSZYYIACO-DJLDLDEBSA-N 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000012994 industrial processing Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000001034 iron oxide pigment Substances 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- XTQHKBHJIVJGKJ-UHFFFAOYSA-N sulfur monoxide Chemical compound S=O XTQHKBHJIVJGKJ-UHFFFAOYSA-N 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 229960005196 titanium dioxide Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000007442 viral DNA synthesis Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01100968 | 2001-01-17 | ||
PCT/EP2002/000163 WO2002056913A2 (fr) | 2001-01-17 | 2002-01-10 | Preparations topiques de brivudine stabilisees |
Publications (1)
Publication Number | Publication Date |
---|---|
UA80673C2 true UA80673C2 (en) | 2007-10-25 |
Family
ID=8176229
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UA2003076388A UA80673C2 (en) | 2001-01-17 | 2002-10-01 | Stabilized brivudine topical formulation |
Country Status (28)
Country | Link |
---|---|
US (1) | US20040087602A1 (fr) |
EP (1) | EP1365772A2 (fr) |
JP (1) | JP2004519460A (fr) |
KR (1) | KR20030070109A (fr) |
CN (1) | CN1236777C (fr) |
AR (1) | AR035530A1 (fr) |
AU (1) | AU2002244642B2 (fr) |
BG (1) | BG107988A (fr) |
BR (1) | BR0206478A (fr) |
CA (1) | CA2434743A1 (fr) |
CZ (1) | CZ20031912A3 (fr) |
EE (1) | EE200300322A (fr) |
HR (1) | HRP20030559A2 (fr) |
HU (1) | HUP0302741A3 (fr) |
IL (1) | IL156933A0 (fr) |
MA (1) | MA26266A1 (fr) |
MX (1) | MXPA03006307A (fr) |
MY (1) | MY136633A (fr) |
NO (1) | NO20033206L (fr) |
PE (1) | PE20020818A1 (fr) |
PL (1) | PL365741A1 (fr) |
RU (1) | RU2280453C2 (fr) |
SK (1) | SK8992003A3 (fr) |
TN (1) | TNSN03036A1 (fr) |
UA (1) | UA80673C2 (fr) |
WO (1) | WO2002056913A2 (fr) |
YU (1) | YU57103A (fr) |
ZA (1) | ZA200305437B (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102005046769A1 (de) * | 2005-09-29 | 2007-04-05 | Berlin-Chemie Ag | Lichtstabile, brivudinhaltige pharmazeutische Formulierung zur Behandlung von Augenherpes (Herpes Ophthalmicus) |
FR2936706B1 (fr) * | 2008-10-08 | 2010-12-17 | Oreal | Composition cosmetique contenant un derive de dibenzoylmethane et un compose dithiolane ; procede de photostabilisation du derive de dibenzoylmethane |
JP5591128B2 (ja) * | 2009-01-29 | 2014-09-17 | 大日本住友製薬株式会社 | 内核を有する口腔内崩壊錠 |
EP3272346A4 (fr) * | 2015-03-19 | 2018-08-01 | Daiichi Sankyo Company, Limited | Colorant contenant une préparation solide |
CN104988791A (zh) * | 2015-06-25 | 2015-10-21 | 广东义晟实业有限公司 | 一种抗病毒添加剂及添加该添加剂的胶水和uv漆 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0072137A1 (fr) * | 1981-08-01 | 1983-02-16 | Beecham Group Plc | Déoxyuridines à activité antivirale |
HU196038B (en) * | 1987-08-07 | 1988-09-28 | Mta Koezponti Kemiai Kutato In | Process for producing antiherpetic pharmaceutics for external use, containing 5-isopropyl-2'-beta-deoxy-uridine |
DE4122337A1 (de) * | 1991-07-05 | 1993-01-14 | Cedona Pharm Bv | Pharmazeutische zubereitung |
FR2737118B1 (fr) * | 1995-07-28 | 1997-09-05 | Oreal | Composition dermatologique ou pharmaceutique, procede de preparation et utilisation |
GB9521454D0 (en) * | 1995-10-19 | 1995-12-20 | Kappa Pharmaceuticals Ltd | Compositions for the treatment of conditions caused by herpes virus |
US6558710B1 (en) * | 1999-06-14 | 2003-05-06 | Helen Rebecca Godfrey | Topical zinc compositions and methods of use |
DE10162593A1 (de) * | 2001-12-19 | 2003-07-03 | Menarini Ricerche Spa | Stabilisierte topische Brivudin-Formulierungen |
-
2001
- 2001-12-24 MY MYPI20015863A patent/MY136633A/en unknown
-
2002
- 2002-01-10 WO PCT/EP2002/000163 patent/WO2002056913A2/fr not_active Application Discontinuation
- 2002-01-10 AU AU2002244642A patent/AU2002244642B2/en not_active Ceased
- 2002-01-10 BR BR0206478-2A patent/BR0206478A/pt not_active IP Right Cessation
- 2002-01-10 CN CNB028037448A patent/CN1236777C/zh not_active Expired - Fee Related
- 2002-01-10 SK SK899-2003A patent/SK8992003A3/sk not_active Application Discontinuation
- 2002-01-10 RU RU2003121639/15A patent/RU2280453C2/ru not_active IP Right Cessation
- 2002-01-10 CZ CZ20031912A patent/CZ20031912A3/cs unknown
- 2002-01-10 PL PL02365741A patent/PL365741A1/xx not_active Application Discontinuation
- 2002-01-10 EE EEP200300322A patent/EE200300322A/xx unknown
- 2002-01-10 CA CA002434743A patent/CA2434743A1/fr not_active Abandoned
- 2002-01-10 IL IL15693302A patent/IL156933A0/xx unknown
- 2002-01-10 HU HU0302741A patent/HUP0302741A3/hu unknown
- 2002-01-10 KR KR10-2003-7009444A patent/KR20030070109A/ko not_active Application Discontinuation
- 2002-01-10 YU YU57103A patent/YU57103A/sh unknown
- 2002-01-10 EP EP02712810A patent/EP1365772A2/fr not_active Withdrawn
- 2002-01-10 JP JP2002557420A patent/JP2004519460A/ja active Pending
- 2002-01-10 MX MXPA03006307A patent/MXPA03006307A/es not_active Application Discontinuation
- 2002-01-10 US US10/466,305 patent/US20040087602A1/en not_active Abandoned
- 2002-01-16 AR ARP020100151A patent/AR035530A1/es not_active Application Discontinuation
- 2002-01-16 PE PE2002000027A patent/PE20020818A1/es not_active Application Discontinuation
- 2002-10-01 UA UA2003076388A patent/UA80673C2/uk unknown
-
2003
- 2003-06-30 MA MA27219A patent/MA26266A1/fr unknown
- 2003-07-08 TN TNPCT/EP2002/000163A patent/TNSN03036A1/fr unknown
- 2003-07-10 BG BG107988A patent/BG107988A/bg unknown
- 2003-07-10 HR HR20030559A patent/HRP20030559A2/hr not_active Application Discontinuation
- 2003-07-15 ZA ZA200305437A patent/ZA200305437B/xx unknown
- 2003-07-15 NO NO20033206A patent/NO20033206L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
PL365741A1 (en) | 2005-01-10 |
NO20033206D0 (no) | 2003-07-15 |
CN1236777C (zh) | 2006-01-18 |
TNSN03036A1 (en) | 2005-04-08 |
MY136633A (en) | 2008-11-28 |
KR20030070109A (ko) | 2003-08-27 |
CN1486185A (zh) | 2004-03-31 |
AU2002244642B2 (en) | 2005-12-15 |
HRP20030559A2 (en) | 2005-06-30 |
YU57103A (sh) | 2006-08-17 |
MA26266A1 (fr) | 2004-09-01 |
WO2002056913A3 (fr) | 2002-11-07 |
CZ20031912A3 (cs) | 2004-01-14 |
PE20020818A1 (es) | 2002-10-21 |
CA2434743A1 (fr) | 2002-07-25 |
SK8992003A3 (en) | 2003-11-04 |
US20040087602A1 (en) | 2004-05-06 |
BR0206478A (pt) | 2003-12-30 |
HUP0302741A3 (en) | 2007-06-28 |
JP2004519460A (ja) | 2004-07-02 |
EE200300322A (et) | 2003-10-15 |
RU2280453C2 (ru) | 2006-07-27 |
WO2002056913A2 (fr) | 2002-07-25 |
IL156933A0 (en) | 2004-02-08 |
HUP0302741A2 (hu) | 2003-11-28 |
ZA200305437B (en) | 2004-07-15 |
EP1365772A2 (fr) | 2003-12-03 |
NO20033206L (no) | 2003-07-15 |
MXPA03006307A (es) | 2003-09-16 |
RU2003121639A (ru) | 2005-02-10 |
AR035530A1 (es) | 2004-06-02 |
BG107988A (bg) | 2004-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4963555A (en) | Formulations of heterocyclic compounds | |
DE19809304A1 (de) | Formulierungen mit antiviraler Wirkung | |
HUE027244T2 (en) | Use of hydroxybenzoic acid esters and analogues in the manufacture of a medicament for the prevention and treatment of viral infection | |
JP2004067576A (ja) | 老化防止剤 | |
GB2080106A (en) | Acyclovin preparations | |
HU198394B (en) | Process for production of synergetic antiviral medical composition | |
HUT72606A (en) | An antivirally active pharmaceutical oil-in-water emulsion containing 9-[(2-hydroxyethoxy)-metyl]guanine(acyclovir) or salt or ester thereof | |
UA80673C2 (en) | Stabilized brivudine topical formulation | |
ES2272689T3 (es) | Dihidro-triterpenos en el tratamiento de infecciones virales, enfermedad cardiovascular, inflamacion, hipersensibilidad o dolor. | |
KR960000432B1 (ko) | 제약학적 생성물 | |
US7223387B2 (en) | Antiviral formulations comprising propylene glycol and an isopropyl alkanoic acid ester | |
KR0133555B1 (ko) | 5-플루오로우라실계 화합물에 기인한 염증의 발생을 억제할 수 있는 비-주사제 형태의 항암조성물 | |
AU2002244642A1 (en) | Stabilized brivudine topical formulations containing metal oxide pigments | |
NZ205587A (en) | Composition comprising undecylenic acid for treating herpes simplex i | |
DE69430545T2 (de) | Verwendung von penciclovir zur behandlung von postherpetischer neuralgie | |
CA2351463C (fr) | Formulations antivirales renfermant du propylene glycol et un ester acide alkanoique d'isopropyle | |
AU768989B2 (en) | Aciclovir compositions containing dimethicone | |
RU2163486C1 (ru) | Средство для лечения псориаза, витилиго и алопеции | |
HU196038B (en) | Process for producing antiherpetic pharmaceutics for external use, containing 5-isopropyl-2'-beta-deoxy-uridine | |
JPH11501625A (ja) | ヒト・ヘルペスウイルス−8の治療に対するペンシクロビルの使用 | |
Ed-Drourh | Justification of the composition of a soft medicinal product for the treatment of herpes infection | |
KR20120103768A (ko) | pH 조절을 통해 안정화된 프룩토오스 1,6-디포스페이트 화합물을 함유하는 피부 외용제 조성물 | |
AU2004279673A1 (en) | Pharmaceutical formulations of xanthogenates and inhibitors of viral nucleic acid replication (e.g. aciclovir) | |
MXPA01005020A (en) | Antiviral formulations comprising propylene glycol and an isopropyl alkanoic acid ester | |
CA2097087A1 (fr) | Combinaison de composes vanilloides et de composes antiviraux nucleosidiques pour le traitement d'infections herpetiques |